Evidence map›Paper›PMID 41236289›Full record

ArticleDermatology practical & conceptual2025

Retrospective Analysis of Second Primary Malignancies in Patients with Mycosis Fungoides and Sézary Syndrome in Croatia.

Mikela Petkovic, Ivana Ilic, Romana Ceovic

Abstract read
In one paragraph

Article in Dermatology practical & conceptual, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Mikela PetkovicDepartment of Dermatology and Venereology, University Hospital Centre Zagreb, Zagreb, Croatia.
Ivana IlicDepartment of Pathology and Cytology, University Hospital Centre Zagreb, Zagreb, Croatia.
Romana CeovicDepartment of Dermatology and Venereology, University Hospital Centre Zagreb, Zagreb, Croatia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPatients with mycosis fungoides (MF) have a higher risk of developing second primary malignancy. The type of second malignancy varies across the studies, and no established guidelines currently exist for screening MF patients.

objectiveTo identify MF and Sézary syndrome (SS) patients at a potentially higher risk of developing a secondary primary malignancy, assess the prevalence of other secondary malignancies, and evaluate whether MF with other primary malignancies leads to a worse prognosis based on MF variants.

methodsThis observational single-center retrospective study followed 84 patients for a minimum of five years.

resultsWe identified 16 patients (19%) with second malignancy, of whom eight (50%) had hematological neoplasms. Among other malignancies, breast cancer was the most common (N=5), followed by other malignancies, including lung cancer, prostate cancer, kidney cancer, and so on. The median age at disease onset was 53.0 years, while median age at second malignancy diagnosis was 60.5 years. No sex predominance was observed. Although not statistically significant, seven of sixteen patients (43.75%) who developed second malignancy had MF variant (such as folliculotropic MF) or Sezary syndrome. Disease progression was more common in patients with MF variant.

conclusionA higher risk for developing a second primary neoplasm was observed. However, additional cancer screening beyond routine age-and sex-appropriate examinations is not yet included in the current guidelines. Based on our findings, we recommend that MF patients undergo regular preventive screenings for the early detection of other primary malignancies.

Identifiers

PMID41236289
PMCPMC12615117

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.